Triple-Negative Breast Cancer (TNBC) Completed Phase 1 / 2 Trials for Pembrolizumab (DB09037)

Also known as: Triple-negative Breast Cancer

IndicationStatusPhase
DBCOND0067309 (Triple-Negative Breast Cancer (TNBC))Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02452424A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid TumorsTreatment